What is Pacritinib and what does it treat
Pacritinib is an oral kinase inhibitor primarily used to treat hematological malignancies such as myelofibrosis. This drug targets the JAK2/FLT3 pathway through a unique mechanism of action, making it particularly suitable for patients with thrombocytopenia. It has the characteristics of high selectivity and minimal side effects.
1. Basic information of drugs
Parkitinib is a small molecule kinase inhibitor that works by selectively inhibiting JAK2 and FLT3 kinases. Its uniqueness lies in its high selectivity towards JAK2, which can avoid inhibition of JAK1 and reduce related side effects.
2. Indications for treatment
(1) Main indications
Mainly used for the treatment of medium to high risk primary or secondary myelofibrosis, especially suitable for patients with thrombocytopenia (platelet count<50 × 10 ^ 9/L).
(2) Other potential applications
Clinical studies have also shown therapeutic potential for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), but these indications have not yet been formally approved.
3. Mechanism of action
Parkitinib exerts its effects through dual inhibition of the JAK2 and FLT3 signaling pathways. JAK2 inhibition can improve symptoms of bone marrow fibrosis, while FLT3 inhibition has additional therapeutic effects on hematological malignancies with FLT3 mutations.
4. Medication characteristics
(1) Dose plan
The recommended starting dose is 200mg twice daily, taken with meals. The dosage should be adjusted according to the patient's tolerance and efficacy, and can be reduced to a minimum of 100mg once daily.
(2) Medication for special populations
Patients with liver dysfunction need to adjust the dosage, and those with severe liver dysfunction should avoid using it. Elderly patients do not require special dosage adjustments, but close monitoring of adverse reactions is necessary.
5. Taboos for special populations
(1) Pregnancy: Animal studies have shown embryotoxicity, and pregnant women should avoid using contraception during treatment.
(2) Breastfeeding period: Medications may be secreted through breast milk, and lactating women need to discontinue medication or feeding.
(3) Pediatric medication: The safety and efficacy of medication for patients under 18 years old have not been established.
- Previous:Is Pacritinib effective
Disclaimer：《What is Pacritinib and what does it treat》Edited and sorted by Seagull Pharmacy's editors. Please contact us in time if there is any infringement. In addition, the suggestions for drug usage, dosage and disease mentioned in the article are only for medical staff's reference, and can not be used as any basis for medication！